4-氮杂吲唑-3-甲酸甲酯 在
Platinum oxide monohydrate 氢气 作用下,
以
溶剂黄146 为溶剂,
反应 4.0h,
以This resulted in 400 mg of the title compound as a yellow solid的产率得到methyl 1H,4H,5H,6H,7H-pyrazolo[4,3-b]pyridine-3-carboxylate
[EN] ANNULATED PYRAZOLES AS BUB1 KINASE INHIBITORS FOR TREATING PROLIFERATIVE DISORDERS<br/>[FR] PYRAZOLES ANNELÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASE BUB1 POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS
申请人:BAYER PHARMA AG
公开号:WO2017157992A1
公开(公告)日:2017-09-21
Compounds of formula (I) and their use as pharmaceuticals.
化合物式(I)及其作为药物的用途。
US9605005B2
申请人:——
公开号:US9605005B2
公开(公告)日:2017-03-28
[EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS D'ALCYNYLE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
申请人:HOFFMANN LA ROCHE
公开号:WO2015025025A1
公开(公告)日:2015-02-26
The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.
The invention relates to compounds of Formula (0):
wherein Q, A
1
-A
8
, R
4
and R
5
and each has the meaning as described herein.
Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.